Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.

Saved in:
Bibliographic Details
Title: Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer.
Authors: Gonzalez-Angulo AM; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX., Lei X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Alvarez RH; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Green MC; Genentech, South San Francisco, CA., Murray JL; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Valero V; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Koenig KB; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Ibrahim NK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Litton JK; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Nair L; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Krishnamurthy S; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Hortobagyi GN; Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Electronic address: fmeric@mdanderson.org.
Source: Clinical breast cancer [Clin Breast Cancer] 2015 Oct; Vol. 15 (5), pp. 325-31. Date of Electronic Publication: 2015 Mar 24.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 100898731 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0666 (Electronic) Linking ISSN: 15268209 NLM ISO Abbreviation: Clin Breast Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1938-0666
DOI:10.1016/j.clbc.2015.03.004